NewLink Genetics (NASDAQ:NLNK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage currently has a $2.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 21.21% from the company’s current price.
According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “
Other analysts have also issued research reports about the company. ValuEngine lowered NewLink Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Robert W. Baird lowered their target price on NewLink Genetics from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, February 28th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $3.75.
NASDAQ:NLNK opened at $1.65 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.33 and a current ratio of 13.33. The company has a market capitalization of $60.39 million, a price-to-earnings ratio of -1.15 and a beta of 1.79. NewLink Genetics has a 12-month low of $1.28 and a 12-month high of $5.61.
NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.04. The firm had revenue of $0.11 million for the quarter. NewLink Genetics had a negative return on equity of 38.63% and a negative net margin of 1,691.08%. Equities research analysts predict that NewLink Genetics will post -0.7 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in NLNK. Paloma Partners Management Co bought a new position in shares of NewLink Genetics during the fourth quarter worth approximately $30,000. Pennsylvania Trust Co bought a new position in shares of NewLink Genetics during the first quarter worth approximately $48,000. Virtu Financial LLC bought a new position in shares of NewLink Genetics during the first quarter worth approximately $60,000. Rhumbline Advisers grew its position in NewLink Genetics by 41.4% during the fourth quarter. Rhumbline Advisers now owns 40,387 shares of the biotechnology company’s stock worth $61,000 after buying an additional 11,830 shares in the last quarter. Finally, State of Wisconsin Investment Board grew its position in NewLink Genetics by 29.8% during the first quarter. State of Wisconsin Investment Board now owns 38,300 shares of the biotechnology company’s stock worth $74,000 after buying an additional 8,800 shares in the last quarter. Institutional investors own 32.58% of the company’s stock.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.